Early bird rates for the Drug Discovery Innovators & Investors (DDII) UK Conference close on 30 September 2026.

Taking place on 4 November 2026 at etc.venues Monument in London, UK, the conference brings together pharma and biotech companies, technology suppliers, academia, start-ups, spin-outs and investors for a focused day of insight, collaboration and networking.

Six reasons to secure your place:

  1. Hear from industry leaders: Chris Molloy (CEO, UK BioIndustry Association) delivers the keynote on how the UK can build on its strengths in discovery, regulation and finance to become a high-value trading nation in medicines R&D over the next 50 years.
  2. Explore how to make clinical trials more effective: Moderated by Thomas Averre (Director, Tarleton Communications), this panel examines the challenges and opportunities facing UK clinical trials, with speakers including Janet Hemingway (Founding Director, iiCON) and Phillippa Brown (Head of Development Operations, GSK).
  3. Expert advice on the UK regulatory landscape: Anusha Foy (VP, Regulatory Affairs, Allucent) and other expert speakers (to be confirmed shortly) will explore how organisations can work efficiently within the UK drug discovery regulatory framework.
  4. Understand how early-stage capital is allocated: Hear perspectives from Sinclair Dunlop (Managing Partner, Epidarex), Sam Goldsmith (Head of Venture Creation, Cell and Gene Therapy Catapult), Ayokunmi Ajetunmobi (Head of Ventures, Pioneer Group) and Tanya Moore (Investment Principal, Cancer Research Horizons Ventures) on funding early-stage drug development in a challenging market.
  5. Concurrent sessions go deeper into the technologies shaping drug discovery: Choose from concurrent sessions covering topics such as why we need to use AI for faster testing / modelling in drug discovery, why AI integration within biotechs and pharma is attractive to investors, and how IP strategy in pharma and biotech is attractive to investors. Speakers include Tim Reason (Founder, Estima Scientific), Dr Paul Brooks (CN Bio Innovations), Dr Andrew Wells (Partner and Head of Chemistry, HGF) and Yogan Patel (Head of Life Sciences & MedTech and Partner, MHA).
  6. Make valuable connections through structured 1:1 networking: Three dedicated networking breaks and a closing drinks reception provide opportunities to connect with potential suppliers, buyers, investors and collaborators. Use the conference app to review delegate profiles and arrange 1:1 meetings in advance.

The conference is supported by Cancer Research Horizons, Gain Therapeutics, BiotechGate, CSEM, HollandBio, One Life Sciences, One Nucleus, SiLA and Zyme Communications as Event Supporters.

Early bird rates close 16 October 2026. Secure your place today.

[EXPLORE THE AGENDA HERE]